Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Hospital-based observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines

Jasmine Shimin Koh a,*, Rebecca Hui Min Hoe a,1, Ming Hui Yong b,1, Hui Jin Chiew a,1, Yihui Goh c,1, Kok Pin Yong b,d,1, Tian Ming Tu a,e, Derrick Wei Shih Chan f, Benjamin Yong-Qiang Tan g, Leonard Leong Litt Yeo c, Amy May Lin Quek c, Isabel Siow g, Monica Saini a, Jasmyn Angon h, Sharmi Rathakrishnan h, Geraldine Jiangyan Chen i, Andrew Che-Fai Hui j, Aftab Ahmad j, Moe Pearl Shwe j, Kevin Tan a, Raymond Chee Seong Seet j, Mingshi Cai k, Si Min Kuo k, Ling Li Foo k, Thirugnanam Umapathi a

a Department of Neurology, National Neuroscience Institute (Tan Tock Seng Hospital Campus), Singapore
b Department of Neurology, National Neuroscience Institute (Singapore General Hospital Campus), Singapore
c Division of Neurology, Department of Medicine, National University Health System, Singapore
d Department of Neurology, Sengkang General Hospital, Singapore
e Division of Neurology, Department of General Medicine, Changi General Hospital, Singapore
f Department of Paediatrics, Neurology Service, KK Women’s and Children’s Hospital, Singapore
g Yong Loo Lin School of Medicine, National University, Singapore
h Department of General Medicine, Khoo Teck Puat Hospital, Singapore
i Clinical Trials and Research Unit, National Neuroscience Institute (Tan Tock Seng Hospital Campus), Singapore
j Division of Neurology, Department of Medicine, Ng Teng Fong General Hospital, Singapore
k National Immunization Registry, Health Promotion Board, Singapore

ARTICLE INFO

Keywords:
SARS-CoV-2
Vaccination
Clinical study
Adverse events
Safety

ABSTRACT

Purpose: We describe the spectrum of acute neurological disorders among hospitalized patients who recently had COVID-19 mRNA vaccination.

Method: We performed a prospective study at 7 acute hospitals in Singapore. Hospitalized patients who were referred for neurological complaints and had COVID-19 mRNA vaccines, BNT162b2 and mRNA-1273, in the last 6 weeks were classified into central nervous system (CNS) syndromes, cerebrovascular disorders, peripheral nervous system (PNS) disorders, autonomic nervous system (ANS) disorders and immunization stress-related responses (ISRR).

Results: From 30 December 2020 to 20 April 2021, 1,398,074 persons (median age 59 years, 54.5% males) received COVID-19 mRNA vaccine (86.7% BNT162b2, 13.3% mRNA-1273, in the last 6 weeks were classified into central nervous system (CNS) syndromes, cerebrovascular disorders, peripheral nervous system (PNS) disorders, autonomic nervous system (ANS) disorders and immunization stress-related responses (ISRR). Eleven of 27 patients with cranial mononeuropathy had Bell’s palsy. Of 33 patients with seizures, only 4 were unprovoked and occurred within 2 weeks of vaccination. All strokes occurred among individuals with pre-existing cardiovascular risk factors. We recorded 2 cases of cerebral venous thrombosis; none were vaccine-induced thrombotic thrombocytopenia. Five had mild flares of immune-mediated diseases.

Conclusion: Our observational study does not establish causality of the described disorders to vaccines. Though limited by the lack of baseline incidence data of several conditions, we observed no obvious signal of serious neurological morbidity associated with mRNA vaccination. The benefits of COVID-19 vaccination outweigh concerns over neurological adverse events.

* Corresponding author at: 11 Jalan Tan Tock Seng, 308433, Singapore.
E-mail address: jasmine.koh.s.m@singhealth.com.sg (J.S. Koh).
1 These authors contributed equally.

https://doi.org/10.1016/j.jns.2021.120030
Received 22 July 2021; Received in revised form 22 September 2021; Accepted 10 October 2021
Available online 13 October 2021
0022-510X/© 2021 Elsevier B.V. All rights reserved.
1. Introduction

Singapore began her vaccination program with the BNT162b2 (Pfizer-BioNTech) vaccine on 30 December 2020, followed by the mRNA-1273 (Moderna) vaccine on 12 March 2021 [1,2], focusing on healthcare workers and elderly individuals [3]. The unprecedented pace of COVID-19 vaccine development and testing [4]; use of novel mRNA technology and large-scale vaccination programs have engendered concerns of adverse events following immunization (AEFI) [5,6], including neurological disorders. The potential for exacerbating pre-existing immune-mediated diseases and development of vaccine-enhanced disease [7], as well as novel adverse events such as vaccine-induced thrombotic thrombocytopenia (VITT) syndrome have contributed to fears of unexpected AEFI from mRNA vaccines [8,9]. Data from the Centres for Disease Control (CDC) Vaccine Adverse Event Reporting System (VAERS), with 51,755,447 vaccine doses administered, did not show an increased rate of neurological disorders [10]. While non-specific symptoms such as headache were common (13.2%), no neurological disorders were identified from a large app-based survey of patients who had received BNT162b2 in the UK [11]. The data from the European Union was also similarly reassuring [12]. This in the context of very high efficacy of these vaccines to protect against COVID-19 infection, hospitalization and severe illness. In a recent study from Mexico, recording 6,536 AEFI in 704,003 patients who had received the first dose of BNT162b2, only 17 patients had neurological disorders deemed serious [13]. To address the safety concerns of serious neurological AEFI, we extended our ongoing study of COVID-19-associated neurological disorders in Singapore public hospitals [14] to describe neurological disorders occurring in patients recently vaccinated with mRNA vaccines.

2. Materials and method

2.1. Study design, setting and patient population

We performed a multi-centre prospective observational cohort study of patients in 7 Singapore public acute hospitals (Fig. 1). We included all sequential hospitalized patients who were referred for neurological complaints and had received at least 1 dose of BNT162b2 or mRNA-1273 vaccines in the last 42 days. We examined a hospital-based cohort to focus on serious neurological AEFI as defined by World Health Organization (WHO) [7]. Immediate and short term AEFIs are conventionally studied over 42 days [15]. The study covered 30 December 2020 to 20 April 2021, when selected high risk population groups (healthcare, frontline workers and elderly individuals) were vaccinated [3]. To contextualize our findings, data from the National Immunization Registry was probed for the total number of vaccinated individuals in the corresponding period. The protocol was approved by the Institutional Review Board (CIRB 2020/2410).

2.2. Data collection and case ascertainment

1. Patients were evaluated at the discretion of the managing neurologist and relevant clinical, radiological and laboratory data collated. Interval between the last vaccine dose and symptom onset (latency) was calculated.
2. Symptoms or disorders that were deemed non-neurological (e.g., musculoskeletal pain, syncope) or secondary to vaccine reactogenicity [16], namely unspecified headache, malaise and myalgia occurring within 24h of vaccination, were excluded.
3. We classified the cases into 4 groups, similar to our previous study [14] where we described 39 patients with neurological disorders from a cohort of 47,572 COVID-19 patients: i) Central nervous system (CNS) syndromes, ii) Cerebrovascular disorders, iii) Peripheral nervous system disorders, iv) Autonomic nervous system disorders.

Fig. 1. Study methodology and flowchart.
nerve system (PNS) disorders (including cranial neuropathies) and
iv) Autonomic nervous system (ANS) disorders. We added a group for
immunization stress-related responses (ISRR), as defined by the
WHO manual on causality assessment of an AEFI [7,17]. This also
includes functional neurological disorders (FND) temporally related
to vaccination.

4. The study team tele-conferenced fortnightly to adjudicate the cases
by consensus.

2.3. Statistical analysis

Categorical variables are summarized as numbers (n) and percent-
ages (%). Continuous variables are expressed as median (interquar-
tile range), and, based on their distribution, compared using t-test and
Mann–Whitney U tests as appropriate.

3. Results

From 30 December 2020 to 20 April 2021, 1,398,074 individuals in
Singapore received COVID-19 mRNA vaccines (86.7% BNT162b2,
13.3% mRNA-1273), of whom 915,344 (65.5%) completed 2 doses.
Median age was 59(15–121) years; 54.5% males. The demographic
profile of the vaccinated group and pace of vaccination according to age
groups are illustrated in Appendix Figs. A.1 and A.2.

During this period, 457 (0.03%) patients were referred for neuro-
logical complaints, median age 67(20–97) years, 281 (61.5%) males;
none had recent symptomatic COVID-19, as the national policy was to
delay vaccination by 6 months post-COVID-19 infection. Four hundred
and thirty-eight patients (95.8%) received BNT162b2 and 19 (4.2%) had
the mRNA-1273 vaccine. Two hundred and seventy-three (59.7%) cases
and thirty-eight patients (95.8%) received BNT162b2 and 19 (4.2%) had
delay vaccination by 6 months post-COVID-19 infection. Four hundred
and thirty-eight patients (95.8%) received BNT162b2 and 19 (4.2%) had
the mRNA-1273 vaccine. Two hundred and seventy-three (59.7%) cases
occurred after the first dose. Seventy-three (16.0%) were grouped into
CNS syndromes, 286 (62.6%) cerebrovascular disorders, 59 (12.9%) 

PNS disorders, none (0%) ANS disorders and 39 (8.5%) ISRR. Median
latency was 9(0–40) days. Table 1 summarizes the key neurological
disorders and their temporal relationship to vaccines.

3.1. CNS syndromes

Median age of the 73 patients was 62(22–94) years, 35 males. Of 33
(7.2%) patients [median age 63(25–85) years, 17 males] who developed
seizures after vaccination, 17 (51.5%) were first-onset seizures; the rest
had pre-existing epilepsy. Twenty-two (66.7%) occurred after the first
dose. Median latency was 10(0–38) days; 21 (63.6%) occurred in the
first 14 days (18 with identified triggers) and 12 (36.4%) between 15
and 42 days (11 with identified triggers). Four (0.9%) patients had first-
onset unprovoked seizures, defined as convulsive episodes occurring in
the absence of a potentially responsible clinical condition, normal
electroencephalogram and unremarkable MRI brain. They did not
require anti-epileptic drugs. Median latency for these 4 patients was 8
(1–15) days.

Four patients (0.9%) [median age 60.5(46–94) years, 2 males] pre-
sented with encephalopathy at median 16(3–26) days after the first
dose. Three were attributed to presumed infections (tuberculosis (TB),
herpes simplex virus (HSV), bacterial translocation from cerebrospinal
fluid leak) and one to diabetic hyperglycaemia. All improved with
treatment.

Two (0.4%) female patients developed optic neuritis (48 and 62
years). One was idiopathic, occurring 33 days after the second dose; the
other had newly-diagnosed aquaporin-4 (AQP-4) antibody-positive
optic neuritis developing 1 day after the first dose. Two (0.4%) female
patients (22 and 38 years) presented with mild, multiple sclerosis (MS)
relapses 17 and 8 days after the first dose. Both were not on disease-
modifying drugs and have had yearly exacerbations at baseline. All 4
patients improved with corticosteroids.

Table 1
Summary of key neurological disorders in disease groups and temporal relationship to vaccine.

| Category                        | Key neurological disorders in each category¹ | Vaccine type | Patients with symptom onset after first dose, n | Median latency, days (range) |
|---------------------------------|---------------------------------------------|--------------|-----------------------------------------------|-----------------------------|
| Central Nervous System syndromes (n = 73) | Seizures (n = 33)                        | BNT162b2 | 31                                             | 10 (0–38)                   |
|                                 |                                             | mRNA-1273  | 2                                               |                             |
|                                 | Encephalopathy (n = 4)                      |             | 4                                               | 16 (3–26)                   |
|                                 | Demyelinating diseases (multiple sclerosis and optic neuritis) (n = 4) |             | 4                                               | 12.5 (1–33)                 |
| Cerebrovascular disorders (n = 286) | All clinical/imaging proven acute ischemic stroke (n = 246) |             | 234                                            | 9 (0–40)                    |
|                                 | Transient ischemic attack (n = 37)           |             | 35                                             | 11 (0–33)                   |
|                                 | Cerebral venous thrombosis (n = 2)          |             | 2                                               | 8.5 (8–9)                   |
| Peripheral Nervous System disorders (n = 59) | Bell’s palsy (n = 11)                  |             | 11                                             | 7 (1–29)                    |
|                                 | Cranial nerve III and VI palsies (n = 11)   |             | 10                                             | 8 (1–14)                    |
|                                 | Guillain-Barré syndrome (n = 2)             |             | 2                                               | 4 (0–8)                     |
| Autonomic Nervous System disorders (n = 0) |                                 |             | 0                                               |                             |
| Immunization Stress Related Response (n = 39) |                                 |             | 39                                             | 2 (0–35)                    |

¹ Cases not presented here include: primary headaches (n = 19), Parkinson’s disease fluctuations (n = 5), dystonia (n = 1), transient global amnesia (n = 4), spondyloytic and ischemic myelopathies (n = 2), acute psychosis (n = 1), central retinal artery occlusion (n = 1), cranial nerve V mononeuropathy (n = 4), vestibular neuritis (n = 1), non-spondyloytic radiculopathy (n = 3), spondyloptic radiculopathy (n = 5), chronic inflammatory demyelinating polyradiculoneuropathy (n = 1), diabetic polyneuropathy (n = 1), myasthenia gravis (n = 2), myopathies (n = 2) and other peripheral vestibulopathies (n = 16).
We recorded 19 (4.2%) primary headaches, 5 (1.1%) Parkinson’s disease fluctuations, 1 (0.2%) dystonia, 4 (0.9%) transient global amnesia, 2 (0.4%) spondylitic and ischemic myelopathies, and 1 (0.2%) acute psychosis.

3.2. Cerebrovascular disorders

Of 286 (62.6%) patients [median age 70(38–97) years, 197 males], 246 (86.0%) had acute ischemic stroke (AIS), 37 (12.9%) transient ischemic attack (TIA), 2 (0.7%) cerebral venous thrombosis (CVT) and 1 (0.4%) isolated central retinal artery occlusion. AIS was proven on neuroimaging in 243 (98.8%), median age 70 (38–97) years, 169 males; of these, 143 (58.8%) occurred after the first dose. Median latency was 9 (0–40) days. All had at least 1 cardiovascular risk factor (age > 50 years, hypertension, hyperlipidaemia, diabetes mellitus, cardiac disease, BMI ≥ 25.0 kg/m², smoking, atrial fibrillation). The stroke subtypes (TOAST classification) were 71 (29.2%) small-vessel, 73 (30.0%) large vessel, 61 (25.1%) cardioembolic, 36 (14.8%) undetermined and 2 (0.8%) other aetiologies (dissection and hypercoagulable state from malignancy). Eleven (4.5%) were ≤ 50 years of age (Appendix Table A.1). Their median latency of 6(0–40) days was similar to the rest of the cohort (p = 0.42). Forty-one (17.3%) patients received revascularization treatments (thrombolysis or endovascular therapy); the rest received standard of care medical therapy. One hundred and forty-four (59.3%) had a good functional outcome [modified Rankin Scale (mRS) 0–2] upon discharge.

Eleven (4.5%) AIS patients [median age 80(64–97) years, 8 males] had thrombocytopenia (Appendix Table A.2), none akin to VITT. Compared to the rest of imaging-proven AIS patients, they were older (median age 80 vs 70 years, p = 0.007), but their median latency was similar (6 vs 9 days, p = 0.29).

Two (0.4%) patients had extensive CVT (60 and 62 years, both females), 9 and 8 days after second dose respectively. Evaluation for prothrombotic factors (Appendix Table A.3) and malignancy for patient 1 was unremarkable. Despite decompressive hemicraniotomy and anti-coagulation with heparin followed by warfarin, she remained neurologically debilitated (mRS 5) 6 weeks later. Patient 2 had a family history of thrombosis (her son had unprovoked pulmonary embolism). Her prothrombotic evaluation (Appendix Table A.3) showed low anti-thrombin III levels (55%, normal range: 80–120%), attributed to acute thrombosis. She improved with anticoagulation, heparin then warfarin, and recovered to mRS 2 upon discharge. None had thrombocytopenia. Anti-Platelet Factor 4 antibodies were not tested in both patients.

3.3. PNS disorders

We encountered 59 (12.9%) patients with PNS disorders [median age 69(28–92) years, 33 males]. All except 3 received BNT162b2. Twenty-seven (5.9%) [median age 69(28–92) years, 13 males] had cranial mononeuropathies. Eleven (2.4%) [median age 66(28–92) years, 5 males] had Bell’s palsy, 6 (54.5%) of whom occurred after the first dose. Median latency was 7(1–29) days. Six (54.5%) patients made partial recovery within 1–2 months, 1 (9.1%) fully recovered at 3 months, while 4 (36.4%) patients are pending reviews.

We recorded 8 (1.8%) isolated cranial nerve (CN) III and 3 (0.7%) CN VI palsies [median age 70(59–83) years, 7 males]. Eight (72.7%) occurred after the first dose. Median latency from the last vaccine dose was 8(1–14) days. Clinical and laboratory data suggested an ischemic mechanism (7 had diabetes mellitus and 9 had hypertension). Seven (63.6%) patients made partial recovery within 1–2 months and 1 (9.1%) fully recovered at 2 months; reviews are pending for the rest. Four (9.0%) patients had unilateral CN V mononeuropathy; 2 had exacerbation of trigeminal neuralgia and 2 transient unilateral face numbness [median age 67.5(59–71) years, all females, median latency 14(1–19) days]. One (0.2%) patient had vestibular neuritis on the same day as his second dose. All improved with symptomatic treatment.

An elderly man developed multiple (left partial III, IV and VI) cranial neuropathies on the same day as his first dose. The rest of his neurological examination, contrast-enhanced MRI brain, spinal tap and nerve conduction studies were normal. However, serum GM1 IgG was markedly raised, suggesting a forme-fruste of Guillain-Barré syndrome (GBS). He improved within a week without immunotherapy. Another elderly man had acute inflammatory demyelinating polyradiculoneuropathy variant of GBS 8 days after the first dose. He improved with intravenous immunoglobulin.

Three (0.7%) patients [median age 70(52–85) years, 2 males] developed unilateral non- spondylotic radiculopathy at median 1(0–14) day. Two (66.7%) occurred after first dose. One was associated with zoster reactivation in the same segments and foot drop that remained at 2 months. Another had a wrist drop that recovered after 2 months.

Five (1.1%) patients with spondylotic radiculopathy, 1 (0.2%) chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 1 (0.2%) diabetic polyneuropathy, 1 (0.2%) myasthenia gravis (MG) and 2 (0.4%) myopathies had symptom exacerbation after vaccination. Another patient developed new-onset, seropositive, non-thymomatous, generalised MG 17 days after BNT162b2 second dose. He improved with corticosteroids and pyridostigmine. There were 16 (3.5%) other cases of peripheral vestibulopathy, including benign paroxysmal positional vertigo.

3.4. ISRR

Thirty-nine (8.5%) patients developed ISRR [median age 51(20–73) years, 16 males]. Of these, 25 (64.1%) occurred after the first dose. Median latency was 2(0–35) days. Seven (17.9%) patients had previous psychiatric illness or functional disorder. Six (15.4%) had previous migraine. Sixteen (41.0%) patients had a single neurological symptom: sensory complaints (n = 9), dizziness (n = 2), headache (n = 2), focal twitching (n = 2), and forgetfulness (n = 1); 23 (59.0%) were poly-symptomatic: sensory (n = 17), motor (10 weakness and 2 cramps), headache (n = 7), giddiness (n = 5), unsteadiness (n = 3), abnormal movement/twitching (n = 2), dysarthria (n = 2), and visual blurring (n = 2). All except one patient improved prior to discharge.

4. Discussion

Our hospital-based study covered a 4-month period during which 1,398,074 people received at least 1 dose of COVID-19 mRNA vaccine. We recorded only 457 patients with a spectrum of neurological disorders encompassing cranial neuropathies, seizures, AIS, CVT and ISRR. Our study adds value to ongoing pharmacovigilance by describing clinical features and outcomes of the disorders seen after mRNA vaccination in a real-world setting. Unlike the pivotal studies, our cohort was predominantly Asian.

Without attempting to establish or refute causality of these disorders to the mRNA vaccines due to the observational nature of our study, we discuss the possible association of neurological disorders to mRNA vaccines by considering:

a) Temporal association and time window of increased risk: This is based on published literature to elucidate a reasonable time relationship to vaccination [15,18].
b) Biological plausibility of the disorders’ association to vaccination, guided by contemporaneous literature, and
c) For individual disorders, we correlate with available baseline incidence data

We then categorized the likelihood of vaccination or a concurrent and coincidental illness explaining the disorder using the WHO AEFI causality assessment, Brighton criteria framework [19]; Appendix Table A.4).
4.1. CNS syndromes - Seizures

Vaccines can trigger seizures, typically within 24 h for inactivated vaccines and 5–12 days after live-attenuated vaccines [15,20]. The risk period is unknown for novel mRNA vaccines and no cases have been reported at the time of writing. Four patients had first-onset unprovoked seizures within the first 15 days following vaccination without underlying predisposition or concurrent disease. However, unprovoked seizures without a cause are not uncommon. The 4 cases out of 1,398,074 vaccinated persons occurring in 4 months fall within the expected baseline incidence in the general population of 1.9–5.1 per 100,000 person-month [21], and could be categorized at best, “probable” vaccine-related. Another 18 patients who had seizures within the first 2 weeks but had an alternative explanation, such as poorly controlled epilepsy, were categorized only as “possible”. The seizures in the remaining 11 patients were deemed as “unlikely” or “unrelated” as they occurred more than 2 weeks after vaccination and had an alternative explanation.

4.2. CNS syndromes – Encephalopathy

The described risk period for meningoencephalitis after vaccination is 21 days [15]. There have been no reported cases of encephalopathy following mRNA vaccine at the time of writing. The 2 patients who presented with meningoencephalitis within this interval would only fall into the “possible” category because their illness could be better-explained by the presumed clinical diagnosis (supported by MR imaging features of TB and HSV infection, but not confirmed microbiologically). The other 2 patients with encephalopathy, who developed illness outside the risk period and had alternative etiologies (CSF leak and hyperglycaemia), were labelled “unlikely” or “unrelated”.

4.3. CNS syndromes – Immune-mediated disorders

Dysimmune processes tend to occur 5–28 days after inactivated vaccines; with additional days added for the incubation period of live attenuated vaccines [18]. One case of new-onset MS 7 days after the first dose of BNT162b2 was reported [22]. However, an observational study of MS patients who received the BNT162b2 vaccine showed relapse rates (2.1% and 1.6% after first and second dose respectively) similar to non-vaccinated patients [23]. Therefore, we categorized the mild MS flares in 2 patients within this time-frame as only “possible” vaccine-related. The association between vaccination and optic neuritis is less clear [24]. However, the AQP-4 antibody positive optic neuritis that occurred only 1 day after BNT162b2 first dose and the idiopathic optic neuritis that developed 33 days after BNT162b2 second dose were likely incidental and classified as “unlikely”. Likewise, the other CNS syndromes recorded were deemed “unlikely” or “unrelated”.

4.4. Cerebrovascular diseases

Common disorders such as stroke may occur coincidentally after vaccination. No relationship was found in a recent study based on a national database in Scotland that recorded 0.82 million people who received BNT162b2 [25]. The 246 AIS cases out of 1,398,074 vaccinated persons we observed over 4 months lies within the expected local baseline incidence of 16.6 per 100,000 person-month [36]. The median age (70 vs 69 years) and stroke subtypes of our imaging-proven AIS patients were similar to that reported previously, including the Singapore Stroke Registry [26,27]. Nevertheless, to address concerns of possible links to mRNA vaccines, we analysed patients who were deemed least likely to develop AIS (age < 50 years), although this would not account for potential interaction between age and vaccination. No pattern with regards to stroke etiology is discerned; nine of 11 patients had at least 2 cardiovascular risk factors (Appendix Table A.1). They also did not have signs of dysimmunity, prothrombotic state or thrombocytopenia. Compared to other AIS patients, we did not find clustering of latency in this group. Overall, the AIS/TIA cases could be explained by pre-existing cardiovascular risk factors and likely occurred independent of the vaccine. We also did not observe any resemblance to VITT; neither did we find any specific stroke pattern nor clustering of latency (6 vs 9 days, \( p = 0.29 \)) in those with thrombocytopenia (Appendix Table A.2).

Majority of CVTs reported post-vaccination have occurred following the adenovirus vector vaccines [28,29]. Recent reports of possible association between mRNA vaccine and CVT [30,31], have been balanced by reassuring data from the Scotland national database [25]. Our 2 CVT cases, 1 idiopathic, the other with family history, could be categorized as “probable” and “possible” vaccine-related respectively. Similar to AIS [32], the challenge to discerning a causal link between CVT and mRNA vaccine is the uncertainty of the risk period.

4.5. PNS disorders

We recorded 11 cases of Bell’s palsy. It is still unclear if the incidence after mRNA vaccines is above the background rate or disproportionate to that of other viral vaccines [2,33–36]. One report estimated a higher incidence of 106 per 100,000 person-years, against the background rate of 15–30 per 100,000 person-years [36]. The EudraVigilance data suggests a greater than 3-fold increase in Bell’s palsy with mRNA vaccines compared to other vaccines [36]. In Singapore, Bell’s palsy incidence after mRNA vaccination is 3.45 per 100,000 person-month [37], at the higher end of the range of background incidence of 1.1–4.4 per 100,000 person-month.

CN III and VI mononeuropathy occurred in 8 and 3 patients respectively. Post-vaccination cranial neuropathies other than Bell’s palsy is rare. There were 68 reports to the US VAERS over a period of more than 20 years. The commonest cranial neuropathies (excluding VII) were III (n = 22), IV (n = 9) and VI (n = 32), occurring largely in isolation at median 9 days. No clustering according to age group or vaccine types was observed [38]. At the time of writing, there was one report of a patient who developed CN VI palsy 2 days after BNT162b2 [39]. Although our patients developed cranial III and VI neuropathies at median 8(1–14) days post vaccination, the link to vaccination is uncertain as these patients also had risk factors for microvascular ischemia. These cases would therefore fall into “possible” category.

The low occurrence of GBS (n = 2) is perhaps surprising given the slightly elevated risk of GBS after influenza vaccine [40]. The national incidence of GBS has not increased since vaccination started compared to a baseline of 9 GBS cases per month pre-COVID (personal communications). We recorded 1 patient with new-onset MG, similar to a recent report of 2 patients who developed MG 1 and 7 days after BNT162b2 second dose [22]. Our 3 patients who had exacerbation of MG, CIDP and myositis (2 already had frequent relapses), together with the 2 MS cases, suggest that mRNA vaccines may only occasionally contribute to flares of immune-mediated disease.

4.6. ISRR

We recorded 39 patients (8.5%) with ISRR, of whom only a small proportion had previous FND or psychiatric illness. Consistent with previous reports [17,41], these patients were younger, a slightly higher proportion were female and majority were polysymptomatic with sensory symptoms being the commonest complaint. There were no clusters of ISRR.

4.7. Comparison with COVID-19 neurology case-mix

WHO had suggested vigilance for potential vaccine-enhanced disease, an AEFI following some live-attenuated vaccines. This refers to a potential increased risk of COVID-19 like disease or its complications. At present, there is no evidence that either of these risks exist for COVID-19
addition, not all the background incidence rates of the disorders therefore do not reflect that of a steady-state vaccination programme. In described were available. Data from a control group comprising un overestimation of normally infrequent AEFI [35]. Our study findings The first 4 months of the vaccine drive was focused on frontline workers versus 11 in our study, during the same period illustrates this point [37]. Whilst CVT is a significant complication of COVID-19 [14,43], whether this condition is related to COVID-19 mRNA vaccines remains unclear [32]. AIS is associated with COVID-19, often in young patients without cardiovascular risk factors but with signs of dysimmunity and pro-thrombotic tendency [14,44]. On the other hand, AIS in our post-vaccine cohort is likely coincidental. We encountered 4 cases each of limited dysautonomia [45] and severe encephalitis [14,46] associated with COVID-19 but none after vaccination.

Our study has several limitations. Investigations were performed at the discretion of the managing neurologist. Not all patients were tested for COVID-19, although none had COVID-19 symptoms and local transmission was less than 5 community cases per day during the study period. As our study was based in public acute hospitals, we would have missed patients consulting outpatient clinics, private hospitals and non-neurologists. The greater number of Bell’s palsy, 25 recorded by Singapore’s drug regulatory authority, Health Sciences Authority (HSA), versus 11 in our study, during the same period illustrates this point [37]. The first 4 months of the vaccine drive was focused on frontline workers and elderly patients (Appendix Fig. A.2), hence our study findings may not be generalizable to the general population. A large number of individuals were vaccinated over a short period of time, engendering overestimation of normally infrequent AEFI [35]. Our study findings therefore do not reflect that of a steady-state vaccination programme. In addition, not all the background incidence rates of the disorders described were available. Data from a control group comprising unvaccinated patients hospitalized in the same period was also unavailable. The published risk periods that guided us might be inapplicable to vaccine cohort is likely coincidental. We encountered 4 cases each of AIS, Bell’s, ISRR, Bell’s with COVID-19, which was not seen in our study cohort. As our study was based in public acute hospitals, we would have missed patients consulting outpatient clinics, private hospitals and non-neurologists. According to the latest study, the number of Bell’s palsy, 25 recorded by Singapore’s drug regulatory authority, Health Sciences Authority (HSA), versus 11 in our study, during the same period illustrates this point [37].

The study was approved by the Singapore Health Services institutional review board for collection of anonymized clinical data.

Data availability statement

Study protocol, statistical code and dataset are available from the corresponding author upon reasonable request. All data relevant to the study are included in the article and supplemental material. Patient-related dataset will be shared upon request from any qualified investigator, maintaining anonymization of the individual patients.

Declaration of Competing Interest

None.
Appendix Fig. A.1. Demographic profile of the national COVID-19 mRNA vaccination program during study period - 30 December 2020 to 20 April 2021. (National Immunization Registry).

Appendix Fig. A.2. Weekly cumulative number of vaccinations by age groups (30 December 2020 to 20 April 2021. (National Immunization Registry).

Appendix Table A.1. Demographics, stroke characteristics and temporal relationship to vaccine of young (≤ 50 years) patients with imaging proven AIS.

| Patient | Age, y/ Sex | Cardiovascular risk factors | Location of infarcts/TOAST classification | Temporal relationship to vaccine, days (after 1st/2nd dose) |
|---------|-------------|-----------------------------|------------------------------------------|--------------------------------------------------------|
| 1       | 43/ female  | Hypertension, BMI 30.1 kg/m² | Left cerebellar infarct/undetermined (cryptogenic) | 40 (after BNT162b2 2nd dose) |
| 2       | 43/ female  | Hypertension, BMI 28.1 kg/m² | Left middle cerebral artery infarct/undetermined (cryptogenic) | 15 (after BNT162b2 1st dose) |
| 3       | 45/ female  | Hypertension, BMI 27.3 kg/m² | Left middle cerebral artery infarct/undetermined | 6 (after BNT162b2 1st dose) |
| 4       | 41/ female  | Smoking (unknown pack years) | Right frontal infarct/large vessel | 25 (after BNT162b2 1st dose) |
| 5       | 38/ female  | Smoking, 10 pack-years | Right parietal infarct | 1 (after BNT162b2 2nd dose) |
| 6       | 42/male     | Hyperlipidemia, Diabetes mellitus | Right thalamus infarct/small vessel | 17 (after BNT162b2 2nd dose) |
| 7       | 47/male     | Hyperlipidemia, Diabetes mellitus, BMI 26.7 kg/m² | Left putamen and corona radiata infarct/small vessel | 2 (after mRNA-1273 1st dose) |

(continued on next page)
### Appendix Table A.2. Demographics, stroke characteristics and temporal relationship to vaccine of imaging proven AIS patients with thrombocytopenia.

| Patient | Age, y/ Sex | Cardiovascular risk factors | Location of infarcts/TOAST classification | Temporal relationship to vaccine, days (after 1st/2nd dose) | Etiology for thrombocytopenia | Initial platelet level, $x 10^9/l$ | Platelet trend |
|---------|-------------|-----------------------------|-------------------------------------------|---------------------------------------------------------------|-----------------------------|---------------------------------|----------------|
| 1       | (81/ male)  | Hypertension, Hyperlipidemia, Diabetes mellitus, Ischemic heart disease, Atrial fibrillation BMI 27.6 kg/m² | Right middle and anterior cerebral artery infarcts/cardioembolic | 23 (after BNT162b2 1st dose) | Chest infection | 119 | Normalized after about 2 weeks |
| 2       | (83/ male)  | Hypertension, Hyperlipidemia, Diabetes mellitus, Ischemic heart disease, Atrial fibrillation BMI 28.4 kg/m² | Left middle and anterior cerebral artery infarcts/cardioembolic | 42 (after BNT162b2 1st dose) | None | 117 | Stable when checked 2 days later |
| 3       | (80/ female) | Hypertension, Smoking | Left corona radiata and lentiform nucleus infarcts/undetermined (cryptogenic) | 28 (after BNT162b2 1st dose) | None | 120 | Improved when checked 2 days later |
| 4       | (74/ male)  | Hypertension, Hyperlipidemia, Old stroke, Smoking | Left pons infarct/small vessel | 2 (after BNT162b2 2nd dose) | None | 115 | Stable when checked 2 days later |
| 5       | (73/ male)  | Hypertension, Hyperlipidemia, Ischemic heart disease, Valvular atrial fibrillation BMI 25.4 kg/m² | Left cerebellar infarct/cardioembolic | 28 (after BNT162b2 1st dose) | None | 118 | Normalized after 5 days |
| 6       | (86/ female) | Hypertension, Atrial fibrillation BMI 25.1 kg/m² | Right middle cerebral artery infarct/cardioembolic | 25 (after BNT162b2 1st dose) | None | 139 | Not repeated |
| 7       | (64/ male)  | Hypertension, Hyperlipidemia, Ischemic heart disease, Old stroke, Smoking | Right putamen, corona radiata and posterior limb internal capsule infarcts/undetermined (cryptogenic) | 10 (after BNT162b2 1st dose) | Alcoholic pancreatitis | 65 | Normalized after 8 days |
| 8       | (68/ female) | Hypertension, Hyperlipidemia, Ischemic heart disease, Diabetes mellitus, Old stroke, Smoking | Left middle cerebral artery infarct/large vessel | 2 (after BNT162b2 1st dose) | Possible urinary tract infection | 123 | Not repeated |
| 9       | (76/ male)  | Hypertension, Hyperlipidemia, Ischemic heart disease, Diabetes mellitus | Right thalamic infarct/large vessel | 6 (after BNT162b2 1st dose) | None | 126 | Normalized when checked about 2 weeks later |
| 10      | (86/ male)  | Hypertension, Atrial fibrillation | Right middle cerebral artery infarct/cardioembolic | 24 (after BNT162b2 1st dose) | None | 139 | Normalized after 6 days |

AIS = acute ischemic stroke; BMI = body mass index; TOAST = Trial of Org 10172 in Acute Stroke Treatment.

---

Appendix Table A.2 (continued) Demographics, stroke characteristics and temporal relationship to vaccine of imaging proven AIS patients with thrombocytopenia.

| Patient | Age, y/ Sex | Cardiovascular risk factors | Location of infarcts/TOAST classification | Temporal relationship to vaccine, days (after 1st/2nd dose) | Etiology for thrombocytopenia | Initial platelet level, $x 10^9/l$ | Platelet trend |
|---------|-------------|-----------------------------|-------------------------------------------|---------------------------------------------------------------|-----------------------------|---------------------------------|----------------|
| 11      | (50/ male)  | Hypertension, Hyperlipidemia, BMI 28.4 kg/m² | Left corona radiata, left lentiform nucleus and right high frontal subcortical infarcts/undetermined | 1 (after BNT162b2 2nd dose) | None | 139 | Normalized after 6 days |

---

**a** Incomplete stroke evaluation as patient declined cardioembolic work-up.

**b** Cardiovascular risk factors include – Age > 50 years, hypertension, hyperlipidemia, diabetes mellitus, cardiac disease, BMI ≥ 25.0 kg/m², smoking, atrial fibrillation.


Table A.3. Pertinent clinical, radiological and laboratory evaluation of patients with cerebral venous thrombosis.

| Patient (Age, y/ Sex) | Cardiovascular risk factors$^a$ | Location of infarcts/TOAST classification | Temporal relationship to vaccine, days (after 1st/2nd dose) | Etiology for thrombocytopenia | Initial platelet level, x 10$^9$/l | Platelet trend |
|------------------------|---------------------------------|------------------------------------------|-------------------------------------------------------|-------------------------------|----------------------------------|---------------|
| 11 (97/ male)          | Hypertension Hyperlipidemia Ischemic heart disease Diabetes mellitus Atrial fibrillation Old stroke BMI 26.8 kg/m$^2$ | Right middle and anterior cerebral artery infarcts/cardioembolic | 2 (after BNT162b2 2nd dose) | None | 130 | Not repeated, background chronic thrombocytopenia |

AIS = acute ischemic stroke; BMI = body mass index; TOAST: Trial of Org 10172 in Acute Stroke Treatment.

$^a$ Cardiovascular risk factors include – Age > 50 years, hypertension, hyperlipidemia, diabetes mellitus, cardiac disease, BMI > 25.0 kg/m$^2$, smoking, atrial fibrillation.

### References

[1] F.P. Polack, S.J. Thomas, N. Kitchin, et al., Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, N. Engl. J. Med. 383 (27) (2020) 2603–2615, https://doi.org/10.1056/NEJMoa2034577.

[2] L.R. Baden, H.M. El Sahly, B. Esinik, et al., Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, N. Engl. J. Med. 384 (5) (2021) 403–416 (Epub 2020 Dec 30).

[3] Ministry of Health Government Accepts Recommendations of Expert Committee on COVID-19 Vaccination [Internet], Ministry of Health, Singapore (SG), 2020 Dec 27 [cited 2021 Jun 14]. Available from: https://www.moh.gov.sg/news-highlights/details/government-accepts-recommendations-of-expert-committee-on-covid-19-vaccination.

[4] D. Calina, T. Hartung, A.O. Docea, et al., COVID-19 vaccines: ethical framework concerning human challenge studies, Daru 28 (2) (2020) 807–812, https://doi.org/10.1007/s40199-020-00371-8.

[5] D. Calina, A.F. Hernández, T. Hartung, et al., Challenges and scientific prospects of the newest generation of mRNA-based vaccines against SARS-CoV-2, Life 11 (9) (2021) 907, https://doi.org/10.3390/life11090907.

[6] N.K. Ronald, K. Darja, L.P. Alan, et al., Vaccine- and natural infection-induced mechanisms that could modulate vaccine safety, Toxicol. Rep. 7 (2020) 1448–1458, https://doi.org/10.1016/j.toxrep.2020.10.016.

[7] World Health Organization. Covid-19 vaccines: safety surveillance manual - monitoring and responding to adverse events following immunization [Internet], World Health Organization, Geneva (CH), 2020 [cited 2021 Jun 14]. 26 p. Available from: https://www.who.int/publications/m/item/covid-19-vaccines-safety-surveillance-manual—monitoring-and-responding-to-adverse-events-following-immunization.

[8] N.H. Schultz, L.H. Sørvoll, A.E. Michelsen, et al., Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination, N. Engl. J. Med. 384 (22) (2021) 2124–2130, https://doi.org/10.1056/NEJMoa2104882 (Epub 2021 Apr 9).

[9] A. Greinacher, T. Thiele, T.E. Warkentin, et al., Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination, N. Engl. J. Med. 384 (22) (2021) 2092–2101.
[10] A.L. Goss, R.D. Samudralwar, R.R. Das, et al., ANA investigates: neurological complications of COVID-19 vaccines, Ann. Neurol. 89 (5) (2021) 856–857, https://doi.org/10.1002/ana.26605 (Epub 2021 Mar 30).

[11] C. Menzi, K. Klaeser, A. May, et al., Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study, Lancet Infect. Dis. 21 (7) (2021 Apr 27) 939–949 (Epub ahead of print).

[12] F.H. Antonio, C. Daniela, P. Konstantinos, et al., Safety of COVID-19 vaccines administered in the EU: should we be concerned? Toxicol. Rep. 8 (2021) 871–879, https://doi.org/10.1016/j.toxrep.2021.04.003.

[13] M. García-Grimshaw, S.E. Ceballos-Liceaga, L.E. Hernández-Vanegas, et al., Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: a nationwide descriptive study. Clin. Immunol. 229 (2021) 108766, https://doi.org/10.1016/j.clim.2021.108766.

[14] J.S. Koh, D.A. De Silva, A.M.L. Quek, et al., Neurology of COVID-19 in Singapore, J. Neurol. Sci. 418 (2020), 117118, https://pubmed.ncbi.nlm.nih.gov/32977228/ (Accessed 14 June 2021).

[15] S.K. Greene, M. Kullaroff, E.M. Lewis, et al., Near real-time surveillance for influenza vaccine safety: proof-of-concept in the vaccine safety datalink project, Epidemiol. Rev. 171 (2) (2010) 177–188 (Epub 2009 Dec 4).

[16] C. Hervé, B. Lauperrière, G. Del Giudice, et al., The how and what of vaccine reactogenicity, NPJ Vaccines. 4 (2019), 39.

[17] World Health Organization. Immunization Stress-related Response: A Manual for Program Managers and Health Professionals to Prevent, Identify and Respond to Stress-related Responses Following Immunization [Internet], World Health Organization, Geneva (CH), 2019 (cited 2021 Jun 14), 62 p. Available from: https://www.who.int/publications/i/item/10665330277.

[18] L.E. Scheffer, Vaccination triggers, rather than causes, Seizure Curr. 15 (4) (2014) 450–452 (Epub 2014 Feb 24).

[19] I.E. Scheffer, Vaccination triggers, rather than causes, seizures, Epilepsy Curr. 15 (4) (2015) 335–337. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657773/.

[20] J. Puliyel, P. Naik, Revised World Health Organization (WHO)’s causality assessment of adverse events following immunization- a critique, F1000Res 7 (2018) 243.

[21] J. Stowe, N. Andrews, L. Wise, et al., Investigation of the temporal association of COVID-19 vaccination and thromboembolic and hemorrhagic events among 704,003 first-dose recipients of the BNT162b2 mRNA SARS-CoV-2 vaccine, J. Stroke Cerebrovasc. Dis. 30 (8) (2021) 1247–1248, https://doi.org/10.1016/j.stcjd.2021.04.003 . (Accessed 16 June 2021).

[22] D.M. Smadja, Q.-Y. Yue, R. Chorron, et al., Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase, Eur. Respir. J. (2021) https://doi.org/10.1183/13993003.00956-2021. https://ejr.ersjournals.com/content/early/2021/04/08/13993303.00956-2021. (Accessed 18 June 2021).

[23] H. Ledford, US authorization of first COVID vaccine marks new phase in safety monitoring, Nature. 588 (7838) (2020) 377–378.

[24] L. Dias, P. Naik, Revised World Health Organization (WHO)’s causality assessment of adverse events following immunization- a critique, F1000Res 7 (2018) 243.

[25] E.J. Woo, S.K. Winiecki, A.C. Ou, Motor palsies of cranial nerves (excluding VII) after vaccination reports to the US vaccine adverse event reporting system, Hum Vaccin Immunother. 10 (2) (2014) 301–305 (Epub 2013 Nov 14).

[26] D.P. Reyes-Capo, S.M. Stevens, K.M. Cavuoto, Acute abducens nerve palsy following COVID-19 vaccination, J. AAPOS. S1091-7357 (21) (2021), 00109 (Epub ahead of print).

[27] T.M. Tu, C.Y.H. Seet, J.S. Koh, et al., Acute ischemic stroke during the convalescent phase of COVID-19 infection in a vaccinated patient, J. Neurol. Neurosurg. Psychiatry 92 (2021) 1247–1248, https://doi.org/10.1136/jnnp-2021-326984.full.pdf. (Accessed 17 June 2021). Epub ahead of print.

[28] J. Diaz, R. Soares-Das-Reis, J. Meira, et al., Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine, J. Stroke Cerebrovasc. Dis. 30 (8) (2021) 105906.

[29] T. Al-Mayhani, S. Saber, M.J. Stubbs, et al., Ilaemusio strain as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombocytopenia, J. Neurol. Neurosurg. Psychiatry 92 (2021) 1247–1248, 326984, https://jnnp-bmj.com.libproxy1.nus.edu.sg/content/jnnp/early/2021/06/03/jnnp-2021-326984.full.pdf. (Accessed 17 June 2021). Epub ahead of print.

[30] T. Al-Mayhani, S. Saber, M.J. Stubbs, et al., Ilaemusio strain as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombocytopenia, J. Neurol. Neurosurg. Psychiatry 92 (2021) 1247–1248, 326984, https://jnnp-bmj.com.libproxy1.nus.edu.sg/content/jnnp/early/2021/06/03/jnnp-2021-326984.full.pdf. (Accessed 17 June 2021). Epub ahead of print.

[31] H. Ledford, US authorization of first COVID vaccine marks new phase in safety monitoring, Nature. 588 (7838) (2020) 377–378.

[32] L. Dias, P. Naik, Revised World Health Organization (WHO)’s causality assessment of adverse events following immunization- a critique, F1000Res 7 (2018) 243.

[33] H. Ledford, US authorization of first COVID vaccine marks new phase in safety monitoring, Nature. 588 (7838) (2020) 377–378.

[34] L. Dias, R. Soares-Das-Reis, J. Meira, et al., Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases, medRxiv (2021), https://doi.org/10.1101/2021.04.27.21256135v1.

[35] J.S. Koh et al., Acute ischemic stroke during the convalescent phase of COVID-19 infection in a vaccinated patient, J. Neurology. Sci. 392 (2021) 113659, https://doi.org/10.1016/j.jns.2021.113659 (Epub ahead of print).

[36] J. Puliyel, P. Naik, Revised World Health Organization (WHO)’s causality assessment of adverse events following immunization- a critique, F1000Res 7 (2018) 243.

[37] J. Puliyel, P. Naik, Revised World Health Organization (WHO)’s causality assessment of adverse events following immunization- a critique, F1000Res 7 (2018) 243.

[38] J. Puliyel, P. Naik, Revised World Health Organization (WHO)’s causality assessment of adverse events following immunization- a critique, F1000Res 7 (2018) 243.